- Home
- ZVIA vs IMMP Comparison
ZVIA vs IMMP Comparison
Compare ZVIA & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVIA
- IMMP
- Stock Information
- Founded
- ZVIA 2007
- IMMP 1987
- Country
- ZVIA United States
- IMMP Australia
- Employees
- ZVIA N/A
- IMMP N/A
- Industry
- ZVIA Beverages (Production/Distribution)
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- ZVIA Consumer Staples
- IMMP Health Care
- Exchange
- ZVIA Nasdaq
- IMMP Nasdaq
- Market Cap
- ZVIA 266.6M
- IMMP 304.0M
- IPO Year
- ZVIA 2021
- IMMP N/A
- Fundamental
- Price
- ZVIA $3.79
- IMMP $1.96
- Analyst Decision
- ZVIA Hold
- IMMP Buy
- Analyst Count
- ZVIA 4
- IMMP 2
- Target Price
- ZVIA $2.69
- IMMP $8.50
- AVG Volume (30 Days)
- ZVIA 947.7K
- IMMP 71.7K
- Earning Date
- ZVIA 02-25-2025
- IMMP 02-27-2025
- Dividend Yield
- ZVIA N/A
- IMMP N/A
- EPS Growth
- ZVIA N/A
- IMMP N/A
- EPS
- ZVIA N/A
- IMMP N/A
- Revenue
- ZVIA $153,385,000.00
- IMMP $2,563,302.00
- Revenue This Year
- ZVIA N/A
- IMMP N/A
- Revenue Next Year
- ZVIA $7.90
- IMMP $47.79
- P/E Ratio
- ZVIA N/A
- IMMP N/A
- Revenue Growth
- ZVIA N/A
- IMMP 9.59
- 52 Week Low
- ZVIA $0.62
- IMMP $1.66
- 52 Week High
- ZVIA $4.99
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- ZVIA 44.68
- IMMP 45.35
- Support Level
- ZVIA $3.60
- IMMP $1.89
- Resistance Level
- ZVIA $4.51
- IMMP $2.16
- Average True Range (ATR)
- ZVIA 0.34
- IMMP 0.09
- MACD
- ZVIA -0.14
- IMMP 0.01
- Stochastic Oscillator
- ZVIA 13.67
- IMMP 24.07
About ZVIA Zevia PBC
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.